Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya

NCT03690648 | Completed

• 1 other identifier: 2016/CHU/12
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Chikungunya virus (CHIKV) infection has become a threat to public health worldwide. Reunion Island, due to the 2005-2006 epidemic, has acquired unique expertise and remains at the forefront of global research on this disease. The idea of genetic determinism of the clinical expression of infectious diseases has been supported by many epidemiological arguments over the past fifty years. The identification of genetic variants, associated with a disease, often allows a better understanding of the molecular mechanisms involved with consequent significant benefits such as the development of specific biomarkers for new preventive (vaccination) and / or therapeutic (drug design) approaches. In the absence of well-documented hypotheses about the genes potentially involved in the occurrence or evolution of a disease, genome-wide association studies (GWAS), whole genome, of nucleotide polymorphisms (SNPs) and the principle of linkage disequilibrium, under the commonly accepted hypothesis that the expression of a common disease is based on a small number of alleles commonly found in the population (frequency of minor allele greater than 1-5%), have become a method of choice, free of hypothesis, to specify the part of heritability of a complex disease and to identify its genetic determinants. Several epidemiological arguments support a significant proportion of genetic determinism in the explanation of the evolutionary pattern of Chikungunya, whose proportion of chronic forms can reach 40-60% in population-based studies conducted in the two years following an epidemic:

• There are few risk factors associated with chronic forms and these appear to be unclear (age, comorbidities with several elements of the metabolic syndrome) or inconsistent (immune burden) in population studies;
• The incidence of severe or atypical forms is rare in the order of 1% of infections;
• In contrast to the acute phase (J1-J21) for which there seems to be a role of the viral load intensity and a consensual pro-inflammatory immune signature according to a recent meta-analysis\]; The role of the intensity of the viral load in the pathogenesis of chronic arthralgia (\> J90) and their immune signature remain to be determined, the latter being rather nonspecific, according to studies conducted in Reunion, Italy or Singapore. These elements justify the interest of a GWAS in the Chikungunya to identify new avenues and mechanistic hypotheses likely to explain the chronic arthralgia characteristic of the disease.

Conditions

Chikungunya Fever

Outcome Measures

Primary Outcomes (1)

• identify by a genome-wide association study the genetic factors associated with the evolutionary profile of Chikungunya

  to determine if certain genetic profiles may be predictive of progression to asymptomatic or acute disease, or to the chronic character of the manifestations of the disease

  through study completion, an average of 1 year

Study Arms (2)

Saliva collection

* Clinical examination; * Quality of life survey; * Saliva collection for genetical analysis

Other: Quality of life survey; Genetic: Saliva collection

Saliva and Blood collection

* Clinical examination; * Quality of life survey; * Saliva and blood collection for genetical analysis

Other: Quality of life survey; Genetic: Saliva collection; Genetic: Blood collection

Interventions

Quality of life survey OTHER

Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD

Saliva and Blood collection; Saliva collection

Saliva collection GENETIC

Collection of 20 ml of saliva with a kit of saliva collection

Saliva and Blood collection; Saliva collection

Blood collection GENETIC

Collection of 20 ml of blood with kit of blood collection

Saliva and Blood collection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subject with a serological status known for Chikungunya virus for the period between March 1st, 2005 and December 31st, 2006 (epidemic period in reunion Island).

You may qualify if:

• Subject of the seroprevalence survey or neighbor living in the same neighborhood likely to confirm an exposure status or known;
• Exposure status established by specific IgG serology, collected between March 1st, 2005 and December 31st, 2006;
• Affiliated to a social security scheme;
• Age between 18 and 75 years old;
• Paternal and maternal 1st and 2nd degree ascendants (parents and grandparents) and at least 3 generations of the family present on the island (grandparents born on the island of Réunion);
• Able to spit

You may not qualify if:

• Exposure status unknown;
• Absence of social security;
• Age \<18 years and\> 75 years;
• Physical inability to spit;
• Pregnant women;
• Protected person (tutorship or curatorship).

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead
• Conservatoire national des Arts et Métiers: collaborator

Study Sites (1)

CHU de La Réunion

Saint-Pierre, 97410, Reunion

Location

Biospecimen

Retention: SAMPLES WITH DNA

Saliva and blood collection for genetical analysis (GWAS)

MeSH Terms

Conditions

Chikungunya Fever

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Alphavirus Infections; Arbovirus Infections; Vector Borne Diseases; Infections; Mosquito-Borne Diseases; Virus Diseases; Togaviridae Infections; RNA Virus Infections

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 26, 2018
• First Posted: October 1, 2018
• Study Start: August 1, 2018
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: August 30, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

RE (1)